Background

Lung adenocarcinoma (LUAD) is the most common type of non-small cell lung cancer and exhibits extreme molecular heterogeneity. While the introduction of Epidermal Growth Factor Receptor (EGFR) or Anaplastic Lymphoma Kinase (ALK) inhibitors has improved treatment outcomes, many patients progress due to a lack of targetable mutations or the acquisition of drug resistance. This creates an urgent need for new target discovery for patient groups with exhausted treatment options.

As large-scale CRISPR functional screening data, such as the Cancer Dependency Map (DepMap), has accumulated, the search for essential genes for cancer cell survival has become active. However, cell line-based screening in culture dishes fails to fully reflect the complexity of the actual patient tumor microenvironment. Relying solely on simple dependency scores exposes the flaw of including a large number of false-positive targets that appear effective in vitro but are not reproducible in actual patient tissues. This background necessitates a computational screening strategy to bridge the gap between laboratory-level functional vulnerabilities and clinical patient cohorts.

Key Findings

The researchers constructed DepPrior, a computational framework based on conjunctive ranking rules that combines multiple criteria. It is structured to strictly prioritize genes that simultaneously satisfy three complementary evaluation criteria.

The first criterion is the separation of CRISPR gene dependency. Clear dependency variations among cell lines allowed for the primary selection of genes that exhibit selective vulnerability only in specific cancer cells. The second criterion for molecular predictability involved training linear and nonlinear machine learning models using gene expression levels and copy-number variation (CNV) data from cell lines as input features. The researchers predicted DepMap dependency scores to calculate the area under the receiver operating characteristic curve (AUROC) and the coefficient of determination (R²) at the gene level. The third is multi-cohort reproducibility. Validation was performed to confirm whether consistent expression patterns were maintained at the transcriptome and proteome levels of patient tumors when compared with large-scale independent clinical databases such as TCGA-LUAD, GEO, and CPTAC.

The researchers designed DepScore, an index combining AUROC and R², to prioritize candidate genes. As a result of the analysis, FERMT2, CRKL, MYC, and CHMP4B were identified as the top lung adenocarcinoma target candidates. These genes show a pattern of robustly forming gene expression modules directly linked to cancer cell proliferation in TCGA-LUAD patient data.

To prove the validity of the computational predictions, orthogonal experimental validation using the lung cancer cell line HCC827 was also performed. Knocking down the expression of FERMT2 and CRKL within the cells resulted in a decrease in target protein levels along with a distinct increase in apoptosis-related signaling proteins. In particular, a synergistic effect was observed where the change in apoptosis-inducing proteins was significantly more amplified under simultaneous inhibition of both genes compared to single-gene inhibition conditions.

Significance and Outlook

DepPrior serves as a bridge smoothly connecting the noise of cell line screening with the complexity of patient tissues. This is due to its design, which integrates functional genomics and patient multi-omics reproducibility into a single pipeline, moving away from the conventional reliance on simple transcriptomic correlation analysis or dependence on single cell lines. It is expected to function as a hypothesis-generating platform that reduces R&D costs and failure rates by narrowing down effective target candidates in the early stages of drug development.

The amplification of apoptosis signals induced by the simultaneous inhibition of FERMT2 and CRKL presents a new possibility for combination therapies in lung adenocarcinoma, which had previously been limited to single-target approaches. Since the study focused on computer-based data prediction and functional inhibition at the cell line level, it also has the limitation that additional rescue experiments are required to demonstrate the structural binding of target proteins. Verification of in vivo drug efficacy and safety using patient-derived cancer organoids and animal xenograft models is also a task to be addressed in the future.